Source of Support: None, Conflict of Interest: None
Seventy patients with Extrinsic Bronchial Asthma were allocated to two treatment groups in random manner. Group I (47 patients) received Ketotifen and Group II (23 patients) Disodium cromoglycate. Other antiasthmatic drugs except antihistamines were continued as required. Clinical status and spirometric lung functions were recorded every two weeks. Significant increase in FVC (2.89 L to 3.09 L in ketotifen, 3.11 L to 3.24 L in cromoglycate group) and FEV1 (1.98 L to 2.29 in ketotifen, 1.99 to 2.28 in cromoglycate group) were observed. The differences between the two groups were not statistically significant.